ARWG - ETF AI Analysis
Top Page
Archer Growth ETF (ARWG)
ARWG, the Archer Growth ETF, earns a solid overall rating driven by strong contributors like Arista Networks and Expeditors International, which benefit from robust financial performance, positive earnings outlooks, and exposure to AI and cloud-related growth. Several other holdings such as NetApp, Synopsys, and Inspire Medical Systems also support the fund with healthy fundamentals, though concerns about high valuations and some bearish technical trends in names like Zscaler, Elastic, and DocuSign temper the rating. The main risk factor is that many holdings share similar challenges around rich valuations and periods of technical weakness, which can increase volatility for investors.
ARWG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 15.28M
- Region
- North America
- Expense Ratio
- 0.85%
- Beta
- 0.90
- Issuer
- Archer Funds
- Inception Date
- Dec 29, 2025
- Dividend Yield
- 0.14%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
ARWG Summary
Archer Growth ETF (ARWG) is an actively managed fund that focuses on U.S. growth companies rather than tracking a specific index. It mainly invests in technology and other fast-growing businesses, aiming to help investors grow their money over the long term. Some of its well-known holdings include Phillips 66 and Arista Networks. Someone might consider this ETF if they want diversified exposure to many growth-focused companies in one simple investment. However, because it leans heavily toward tech and other growth stocks, its price can rise and fall more sharply than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.85%, which means you’ll pay about $8.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, with managers selecting specific growth stocks rather than just tracking a simple index.
What would affect this ETF?
ARWG could benefit if the U.S. economy continues to grow, supporting demand for financial, industrial, and consumer cyclical companies, and if innovation-driven businesses like Reddit and other growth names keep attracting users and revenue. On the other hand, higher interest rates, a slowdown in U.S. growth, or tighter regulations affecting financial firms, tech platforms, or airlines could hurt these sectors and weigh on the ETF’s performance.
ARWG Top 10 Holdings
ARWG is leaning heavily into U.S. tech, with names like NetApp and Appian doing much of the heavy lifting as their cloud and AI stories keep the stocks rising. Zscaler and DocuSign are also contributing, though their momentum looks a bit mixed as rich valuations start to weigh. Outside tech, Zebra Technologies and Expeditors International provide steadier industrial ballast, while Inspire Medical Systems has been lagging and occasionally drags on returns. Overall, this is a growth-first, tech-centric U.S. portfolio with a few non-tech players smoothing out the ride.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ZS | Zscaler | 3.37% | $514.23K | $38.78B | -26.15% | 60Neutral |
 APPN | Appian | 3.06% | $467.25K | $3.52B | 64.71% | 58Neutral |
 NTAP | NetApp | 2.93% | $446.89K | $39.12B | 72.35% | 76Outperform |
 ANET | Arista Networks | 2.88% | $439.55K | $212.97B | 6.58% | 83Outperform |
 INSP | Inspire Medical Systems | 2.92% | $446.58K | $1.97B | -6.80% | 73Outperform |
 ZBRA | Zebra Tech | 2.85% | $435.50K | $17.09B | 38.22% | 72Outperform |
 EXPD | Expeditors International | 2.91% | $444.39K | $25.85B | 65.45% | 80Outperform |
 DOCU | DocuSign | 2.78% | $425.31K | $15.36B | 14.75% | 71Outperform |
 ESTC | Elastic | 2.69% | $411.44K | $10.31B | 10.06% | 65Neutral |
 SNPS | Synopsys | 2.73% | $417.64K | $89.61B | 5.57% | 73Outperform |
ARWG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARWG, the sentiment is Negative. The current price of 25.10 is below the 20-day moving average (MA) of 25.84, below the 50-day MA of 25.87, and below the 200-day MA of 25.21, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 41.02 is Neutral, neither overbought nor oversold. The STOCH value of 63.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARWG.
ARWG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ARWG | $25.10 | $28.00(11.55% Upside) | $15.28M | 0.85% | 69Neutral |
 TSEL | $26.78 | $36.53(36.42% Upside) | $76.92M | 0.67% | 70Neutral |
 ZDIS | $54.97 | $79.25(44.17% Upside) | $63.77M | 0.75% | 64Neutral |
 SEMG | $27.25 | $34.45(26.41% Upside) | $63.84M | 0.60% | 72Outperform |
 JGRW | $28.41 | $34.25(20.58% Upside) | $62.28M | 0.57% | 75Outperform |
 NSIG | $23.87 | $31.79(33.18% Upside) | $60.29M | 0.38% | 74Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARWG | Archer Growth ETF | 25.10 | 0.43 | 1.74% | |
| TSEL | Touchstone Sands Capital US Select Growth ETF | 26.78 | -3.46 | -11.45% | |
| ZDIS | Virtus Zevenbergen Discovery Growth ETF | 54.97 | -8.87 | -13.89% | |
| SEMG | Suncoast Select Growth ETF | 27.25 | 0.12 | 0.46% | |
| JGRW | Jensen Quality Growth ETF | 28.41 | 1.50 | 5.56% | |
| NSIG | North Square Growth Opportunities ETF | 23.87 | -1.44 | -5.68% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.